Bristol-Myers Squibb (NYSE: BMY) director adds deferred share units
Rhea-AI Filing Summary
Bristol-Myers Squibb Company director Derica W. Rice reported an equity-related transaction involving deferred share units. On 12/31/2025, Rice acquired 695.217 deferred share units of Bristol-Myers Squibb common stock at a price of $0 per unit. Following this transaction, Rice beneficially owned 34,934.653 deferred share units.
Each deferred share unit will be converted into one share of common stock upon settlement. The units become settleable when Rice ceases to be a director or at a future date previously specified. The holdings include deferred compensation and dividends reinvested under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Deferred Share Units | 695.217 | $0.00 | $0.00 |
Footnotes (2)
- F1. Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.
- F2. Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
FAQ
What insider transaction did Bristol-Myers Squibb (BMY) report for Derica W. Rice?
Derica W. Rice, a director of Bristol-Myers Squibb, reported acquiring 695.217 deferred share units of the company’s common stock on 12/31/2025 at a price of $0 per unit.
What is the role of Derica W. Rice at Bristol-Myers Squibb (BMY)?
Derica W. Rice is reported as a director of Bristol-Myers Squibb Company in the filing.
AI-generated analysis. How Rhea-AI works. Not financial advice.